Chemotherapy’s effectiveness varies enormously depending on the type of cancer, how advanced it is, and whether the goal is to cure the disease or slow its progression. For some cancers, chemotherapy cures more than 90% of patients. For others, it extends life by months rather than years. There is no single answer because chemotherapy is not a single treatment; it’s a broad category of drugs used in very different situations with very different expectations.
Where Chemotherapy Works Best
Chemotherapy is most effective against cancers that grow quickly, because the drugs target cells in the process of dividing. This is why certain fast-growing cancers respond remarkably well. Testicular cancer is the standout example: cure rates exceed 90% for all stages of seminoma combined, and approach 100% for early-stage disease. Even when testicular cancer has spread, a 2006 pooled analysis of chemotherapy trials found survival rates of 94% for good-risk patients, 83% for intermediate-risk, and 71% for poor-risk groups.
Childhood leukemia is another major success story. In acute lymphoblastic leukemia (ALL), the most common childhood cancer, approximately 98% of children achieve remission with chemotherapy. About 85% of patients aged 1 to 18 become long-term event-free survivors, and more than 90% are alive at five years. That’s up from a 60% five-year survival rate in earlier decades, driven almost entirely by improvements in chemotherapy protocols.
Hodgkin lymphoma, certain aggressive non-Hodgkin lymphomas, and some ovarian cancers also fall into the highly curable category when treated with chemotherapy, often in combination with other approaches.
Chemotherapy After Surgery
For many solid tumors, chemotherapy is given after surgery to eliminate microscopic cancer cells that may have been left behind. This is called adjuvant chemotherapy, and its effectiveness is measured by how much it improves survival compared to surgery alone.
In stage 3 colorectal cancer, completing chemotherapy after surgery is associated with a 30% increase in five-year survival rates. That’s a substantial benefit, which is why oncologists strongly recommend it for this group. For breast cancer, the benefit of adjuvant chemotherapy depends heavily on the tumor’s biology, which is where genomic testing has changed the game.
A widely used test assigns breast tumors a recurrence score from 0 to 100. Patients with scores below 18 generally see no benefit from adding chemotherapy to hormone therapy. Those with scores above 30 clearly benefit, with their risk of distant recurrence dropping significantly. The gray zone between 18 and 30 has been the subject of major clinical trials, with evidence suggesting that younger patients (45 and under) in this range do benefit from chemotherapy, while older patients often do just as well with hormone therapy alone.
Chemotherapy Before Surgery
Sometimes chemotherapy is given before surgery to shrink a tumor, making it easier to remove or allowing for less extensive surgery. This approach, called neoadjuvant chemotherapy, provides a built-in measure of effectiveness: if the tumor disappears completely by the time of surgery (a pathologic complete response, or pCR), outcomes tend to be significantly better.
Overall, about 27% of breast cancer patients achieve a complete response with neoadjuvant chemotherapy, but rates differ sharply by subtype. HER2-positive tumors respond best, with pCR rates around 42%, rising to 50% or higher with targeted therapy combinations. Triple-negative breast cancers achieve pCR in roughly 22% of cases, while hormone receptor-positive tumors respond at only about 12%. For patients who do achieve a complete response, the survival advantage is dramatic: the risk of death decreases by 84% in triple-negative breast cancer and 92% in HER2-positive disease.
When the Goal Is Not a Cure
For cancers that have spread widely and cannot be cured, chemotherapy is often used to control growth, relieve symptoms, and extend life. This is palliative chemotherapy, and its benefits are measured in months rather than cure rates.
In metastatic colorectal cancer, for example, patients receiving palliative chemotherapy had a median overall survival of 12.4 months, compared to 5.3 months for those receiving only supportive care. That’s roughly seven additional months. For other metastatic cancers, the survival benefit can be smaller or larger depending on how responsive the tumor is. The tradeoff between extra time and side effects from treatment is a deeply personal calculation, and one reason oncologists discuss goals of care carefully with patients in this situation.
How Chemotherapy Actually Works
Chemotherapy drugs kill cancer cells by interfering with their ability to copy DNA and divide. Some drugs work during all phases of a cell’s life cycle, meaning they can damage both resting and actively dividing cells. Alkylating agents fall into this category. They chemically modify DNA so that the two strands can’t separate properly, blocking replication.
Other drugs only work during specific phases. Antimetabolites are most active when a cell is copying its DNA, while plant-derived drugs target cells in the process of physically splitting into two. This distinction matters in treatment design: combining drugs that work at different phases of the cell cycle hits the cancer from multiple angles and reduces the chance that some cells will escape unharmed.
Why Chemotherapy Stops Working
One of the biggest challenges in chemotherapy is drug resistance. Cancers can become resistant through several mechanisms, and sometimes through multiple mechanisms at once.
The most well-studied form involves molecular pumps on the surface of cancer cells. These proteins, called efflux pumps, actively push chemotherapy drugs out of the cell before they can do enough damage. When these pumps are overproduced, the drug concentration inside the cell stays too low to be lethal. This is particularly problematic in brain tumors, where efflux pumps in blood vessel walls already limit how much drug can reach the tumor in the first place.
Cancer cells also develop enhanced DNA repair abilities, essentially fixing the damage chemotherapy inflicts before it triggers cell death. Genetic mutations can alter the drug’s target so it no longer binds effectively. And some cancer cells shift their metabolism to break down drugs faster. These overlapping defenses explain why cancers that initially respond well to chemotherapy can eventually stop responding, and why oncologists often switch to different drug combinations when resistance develops.
Predicting Who Will Benefit
Cancer treatment has moved increasingly toward predicting chemotherapy’s effectiveness before starting it. Genomic tests in breast cancer are the most established example, but the principle is expanding to other cancers. Genetic testing of tumors can reveal specific mutations that make a cancer more or less likely to respond to particular drugs.
In colorectal cancer, for instance, tumors with specific mutations (like BRAF V600E) now have targeted chemotherapy combinations tailored to their biology. Current guidelines also recommend testing for genetic variants that affect how your body processes certain chemotherapy drugs. Some people metabolize these drugs unusually slowly, leading to severe toxicity at standard doses. Identifying this before treatment starts allows for dose adjustments that maintain effectiveness while reducing harm.
The broader trend is clear: chemotherapy is becoming less of a one-size-fits-all approach. The same drug that offers a major survival benefit for one patient may offer little benefit for another with what appears to be the same cancer but has different molecular characteristics. This is why two people with the same cancer type and stage can receive different treatment recommendations, and why both recommendations can be correct.